Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $84,875.

  • Immuneering's Capital Expenditures fell 94.53% to $9,356 in Q4 2024 from the same period last year, while for Dec 2024 it was $84,875, marking a year-over-year decrease of 75.24%. This contributed to the annual value of $84,875 for FY2024, which is 75.24% down from last year.
  • Per Immuneering's latest filing, its Capital Expenditures stood at $84,875 for FY2024, which was down 75.24% from $342,746 recorded in FY2023.
  • In the past 5 years, Immuneering's Capital Expenditures registered a high of $742,483 during FY2022, and its lowest value of $53,415 during FY2020.
  • Its 3-year average for Capital Expenditures is $390,035, with a median of $342,746 in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 1,121.47% in 2022, then slumped by 75.24% in 2024.
  • Immuneering's Capital Expenditures (Yearly) stood at $53,415 in 2020, then grew by 13.80% to $60,786 in 2021, then surged by 1,121.47% to $742,483 in 2022, then plummeted by 53.84% to $342,746 in 2023, then plummeted by 75.24% to $84,875 in 2024.